Lachlan E McInnes1, Carleen Cullinane2, Peter D Roselt3, Susan Jackson2, Benjamin J Blyth2, Ellen M van Dam4, Nicholas A Zia1, Matthew J Harris4, Rodney J Hicks2,3, Paul S Donnelly5. 1. School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia. 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. 3. Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and. 4. Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia. 5. School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia pauld@unimelb.edu.au Rod.Hicks@petermac.org.
Abstract
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
Authors: A P Kozikowski; F Nan; P Conti; J Zhang; E Ramadan; T Bzdega; B Wroblewska; J H Neale; S Pshenichkin; J T Wroblewski Journal: J Med Chem Date: 2001-02-01 Impact factor: 7.446
Authors: Rodney J Hicks; Price Jackson; Grace Kong; Robert E Ware; Michael S Hofman; David A Pattison; Timothy A Akhurst; Elizabeth Drummond; Peter Roselt; Jason Callahan; Roger Price; Charmaine M Jeffery; Emily Hong; Wayne Noonan; Alan Herschtal; Lauren J Hicks; Amos Hedt; Matthew Harris; Brett M Paterson; Paul S Donnelly Journal: J Nucl Med Date: 2018-11-15 Impact factor: 10.057
Authors: M N Pangalos; J M Neefs; M Somers; P Verhasselt; M Bekkers; L van der Helm; E Fraiponts; D Ashton; R D Gordon Journal: J Biol Chem Date: 1999-03-26 Impact factor: 5.157
Authors: Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Ali Afshar-Oromieh; John W Babich; Clemens Kratochwil; Frederik L Giesel; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2016-10 Impact factor: 10.057
Authors: Carleen Cullinane; Charmaine M Jeffery; Peter D Roselt; Ellen M van Dam; Susan Jackson; Kevin Kuan; Price Jackson; David Binns; Jessica van Zuylekom; Matthew J Harris; Rodney J Hicks; Paul S Donnelly Journal: J Nucl Med Date: 2020-05-15 Impact factor: 10.057
Authors: Peter Kletting; Anne Thieme; Nina Eberhardt; Andreas Rinscheid; Calogero D'Alessandria; Jakob Allmann; Hans-Jürgen Wester; Robert Tauber; Ambros J Beer; Gerhard Glatting; Matthias Eiber Journal: J Nucl Med Date: 2018-05-10 Impact factor: 10.057
Authors: Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy Journal: Lancet Date: 2020-03-22 Impact factor: 79.321
Authors: Truc T Huynh; Ellen M van Dam; Sreeja Sreekumar; Cedric Mpoy; Benjamin J Blyth; Fenella Muntz; Matthew J Harris; Buck E Rogers Journal: Pharmaceuticals (Basel) Date: 2022-06-08
Authors: Laura De Nardo; Gaia Pupillo; Liliana Mou; Juan Esposito; Antonio Rosato; Laura Meléndez-Alafort Journal: Med Phys Date: 2022-02-20 Impact factor: 4.506